Jon Jones and Bourbon, thank you both for reporting and asking questions at the ASM!
“Genomic signature found and to be reported at an upcoming conference. The signature allows them to accurately predict who will benefit most from 2-73. This way the data can be used in all future trials. “
I am wondering, as before, whether the signature found is an indication that high A2-73 blood concentration will be reached by selecting those patients and thereby good response -can either of you tell or have a sense of that from the discussion with Missling?
The Ariana KEM analysis presentation indicated a strong correlation between drug blood concentration and response to A2-73 supporting that idea, whereas the outlier with low concentration responding very well indicates otherwise. This still puzzles me, but I guess I may have to wait for the answer just like everyone else :-)